Novartis files Lescol/Lescol XL sNDAs
This article was originally published in Pharmaceutical Approvals Monthly
Novartis submits sNDAs for Lescol and Lescol XL (fluvastatin) for secondary prevention of cardiovascular events in patients who have undergone percutaneous coronary intervention (PCI) August 1, based on the four-year Lescol Intervention Prevention Study (LIPS). The study, published June 26 in the Journal of the American Medical Association, found that fluvastatin treatment in patients "with average cholesterol levels undergoing their first PCI significantly reduces the risk of major adverse cardiac events." Novartis is touting fluvastatin as the first statin to seek such an indicatio
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”